| Entry |
|
|---|
| Name |
Fulvestrant (JAN/USAN/INN);
Faslodex (TN)
|
|---|
| Product |
|
|---|
| Formula |
C32H47F5O3S
|
|---|
| Exact mass |
606.3166
|
|---|
| Mol weight |
606.7708
|
|---|
| Structure |
     |
|---|
| Activity |
Treatment of breast cancer [antiestrogen] [DS: H00031]
|
|---|
| Remark |
Therapeutic category: ATC code: |
|---|
| Comment |
selective estrogen receptor downregulator (SERD)
|
|---|
| Target |
estrogen receptor 1 antagonist [HSA: 2099] [KO: K08550]; estrogen receptor 2 antagonist [HSA: 2100] [KO: K08551] |
|---|
| Interaction |
Genomic biomarker: Estrogen receptor [HSA: 2099 2100] positive
 |
|---|
| Structure map |
| Antineoplastics - hormones | | Progesterone, androgen and estrogen receptor agonists/antagonists |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D01161 Fulvestrant (JAN/USAN/INN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L02 ENDOCRINE THERAPY
L02B HORMONE ANTAGONISTS AND RELATED AGENTS
L02BA Anti-estrogens
L02BA03 Fulvestrant
D01161 Fulvestrant (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Estrogen like receptors
Estrogen receptor
estrogen receptor 1 [HSA:2099] [KO:K08550]
Fulvestrant [ATC:L02BA03]
D01161 Fulvestrant (JAN/USAN/INN)
estrogen receptor 2 [HSA:2100] [KO:K08551]
Fulvestrant [ATC:L02BA03]
D01161 Fulvestrant (JAN/USAN/INN)
Antineoplastics [BR:br08308]
Hormones and hormone antagonist
Estrogen antagonist
Fulvestrant [ATC:L02BA03]
D01161 Fulvestrant (JAN/USAN/INN)
 |
|---|
| Other DBs |
CAS: 129453-61-8 PubChem: DrugBank: LigandBox: NIKKAJI: |
|---|
| KCF data |
ATOM 41
1 C8x C 7.4203 -16.5528
2 C8y C 7.4203 -17.9330
3 C8x C 8.6185 -18.6231
4 C8x C 8.6185 -15.8628
5 C8y C 9.8096 -16.5528
6 C8y C 9.8037 -17.9330
7 C1x C 10.9960 -18.6281
8 C1y C 12.1942 -17.9432
9 C1y C 11.0077 -15.8679
10 C1y C 12.1942 -16.5658
11 C1x C 12.2169 -13.8129
12 C1x C 11.0191 -14.4913
13 C1z C 13.4035 -14.5109
14 C1y C 13.3866 -15.8831
15 C1x C 15.7638 -15.9121
16 C1x C 15.7803 -14.5396
17 C1y C 14.6003 -13.8392
18 O1a O 14.7331 -12.4541
19 O1a O 6.2253 -18.6237
20 C1b C 13.3801 -18.6301
21 C1b C 14.5721 -17.9469
22 C1b C 15.7641 -18.6370
23 C1b C 16.9561 -17.9539
24 C1b C 18.1480 -18.6440
25 C1b C 19.3400 -17.9609
26 C1b C 20.5319 -18.6510
27 C1b C 21.7239 -17.9678
28 C1b C 22.9159 -18.6579
29 S4a S 24.1078 -17.9748
30 C1b C 25.2998 -18.6649
31 C1b C 26.4917 -17.9819
32 C1b C 27.6837 -18.6720
33 C1d C 28.8756 -17.9887
34 O3c O 24.1108 -16.5946
35 X F 29.9914 -17.2156
36 X F 27.8928 -17.0058
37 C1a C 13.3941 -13.1303
38 C1d C 29.8649 -18.9778
39 X F 30.8541 -19.9671
40 X F 31.0764 -18.2784
41 X F 28.6534 -19.6773
BOND 44
1 4 1 1
2 2 19 1
3 1 2 2
4 8 20 1 #Down
5 9 10 1
6 20 21 1
7 10 14 1
8 21 22 1
9 13 11 1
10 22 23 1
11 11 12 1
12 23 24 1
13 12 9 1
14 24 25 1
15 2 3 1
16 25 26 1
17 3 6 2
18 26 27 1
19 5 6 1
20 27 28 1
21 6 7 1
22 28 29 1
23 7 8 1
24 29 30 1
25 13 14 1
26 30 31 1
27 15 16 1
28 31 32 1
29 16 17 1
30 32 33 1
31 17 13 1
32 29 34 2
33 14 15 1
34 8 10 1
35 17 18 1 #Up
36 9 5 1
37 33 35 1
38 5 4 2
39 33 36 1
40 13 37 1 #Up
41 33 38 1
42 38 39 1
43 38 40 1
44 38 41 1
|
|---|
